Pegvisomant: razlika med redakcijama

dodanih 12 zlogov ,  pred 1 mesecem
m
dp
(n, po en)
 
m (dp)
| Verifiedfields = changed
}}
'''Pegvisomant''' (s tržnim imenom '''Somavert''') je [[Receptorski antagonist|antagonist]] (zaviralec) receptorja [[Rastni hormon|rastnega hormona]] (somatotropina<ref>{{Navedi splet|title=Termania - Slovenski medicinski slovar - somatotropín|url=https://www.termania.net/slovarji/slovenski-medicinski-slovar/5539149/somatotropin?ld=95&query=somatotropin&SearchIn=Linked|website=www.termania.net|accessdate=2021-06-21}}</ref>), ki se uporablja za zdravljenje [[Akromegalija|akromegalije]]<ref name="Schreiber">{{cite journal|vauthors=Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ|date=January 2007|title=Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study|journal=European Journal of Endocrinology|volume=156|issue=1|pages=75–82|doi=10.1530/eje.1.02312|pmid=17218728|doi-access=free}}</ref> in [[Gigantizem|gigantizma]].<ref>{{Navedi revijo|last=Rix|first=M.|last2=Laurberg|first2=P.|last3=Hoejberg|first3=A. S.|last4=Brock-Jacobsen|first4=B.|date=2005-08|title=Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl|url=https://pubmed.ncbi.nlm.nih.gov/16061823/|magazine=European Journal of Endocrinology|volume=153|issue=2|pages=195–201|doi=10.1530/eje.1.01956|issn=0804-4643|pmid=16061823}}</ref><ref>{{Navedi revijo|last=Müssig|first=K.|last2=Gallwitz|first2=B.|last3=Honegger|first3=J.|last4=Strasburger|first4=C. J.|last5=Bidlingmaier|first5=M.|last6=Machicao|first6=F.|last7=Bornemann|first7=A.|last8=Ranke|first8=M. B.|last9=Häring|first9=H.-U.|date=2007-03|title=Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma|url=https://pubmed.ncbi.nlm.nih.gov/17427111/|magazine=Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association|volume=115|issue=3|pages=198–202|doi=10.1055/s-2007-956172|issn=0947-7349|pmid=17427111}}</ref> Uporablja se predvsem, kadar tumorjev [[Hipofiza|hipofiznega tkiva]], ki povzročajo akromegalijo ali gigantizem, ni mogoče nadzorovati s pomočjo kirurških posegov ali [[Obsevanje|obsevanja]], neuspešna pa je tudi aplikacija analogov [[Somatostatin|somatostatina]]. Zdravilo je koristno tudi v primeru [[Monoterapija|monoterapije]] (zdravljenja z zgolj enim zdravilom).<ref name="ReferenceA">{{cite journal|vauthors=Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ|date=March 2015|title=Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY|journal=Endocrine Practice|volume=21|issue=3|pages=264–74|doi=10.4158/EP14330.OR|pmc=4618502|pmid=25370326}}</ref> Pegvisomant se aplicira v obliki praška, pomešanega z vodo in injiciranega pod kožo ([[subkutana aplikacija]]).<ref name="ema">{{cite report|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000409/WC500054625.pdf|title=Scientific Discussion of Somavert|date=2004|publisher=[[European Medicines Agency]]}}</ref>
 
== Odkritje ==